Compare Amgen, Inc. (AMGN) vs Barrick Gold Corp (B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Barrick Gold Corp — how do they compare? Amgen, Inc. trades at $413.61 (market cap $225.71B), while Barrick Gold Corp trades at $40.48 (market cap $68.49B). The key difference: Amgen, Inc. is far larger — about 3.3× Barrick Gold Corp's market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AMGN | B | |
|---|---|---|
Market Cap | $225.71B | $68.49B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $52.97 |
52-Week Low | $271.18 | $22.83 |
Enterprise Value | $269.02B | $66.08B |
Dividend Yield | 2.42% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
Barrick Mining (B) trades at $43.69, up 5.49% in 24 hours, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a $1.95 billion settlement with Newmont, and a robust cash flow trend highlight operational strength. The stock is near its consensus price target of $50.17, supported by a 66.67% analyst buy rating.
The outlook is positive due to earnings growth, favorable valuations, and strategic initiatives like the North American IPO. Risks include gold price volatility and execution of expansion plans. Upside potential exists if the company maintains its earnings momentum and capitalizes on gold market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
